Skip to content

Cohort study of Thromboelastography combined with CYP2C19 genotyping to optimize the efficacy and long-term adverse events of antiplatelet agents after coronary artery bypass grafting

Cohort study of Thromboelastography combined with CYP2C19 genotyping to optimize the efficacy and long-term adverse events of antiplatelet agents after coronary artery bypass grafting

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081401
Enrollment
Unknown
Registered
2024-02-29
Start date
2018-04-08
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary arterie bypass grafting

Interventions

Ischemic group and non-ischemic group
Bleeding group and non-bleeding group
High platelet reactivity group and normal platelet reactivity group:Take clopidogrel and aspirin

Sponsors

Hainan General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Patients after coronary artery bypass transplantation

Exclusion criteria

Exclusion criteria: ? Contraindicated aspirin and clopidogrel ? Participants in other drug trials ? Recent active bleeding disease ? Platelet count =100x10^9/L, hemoglobin concentration < 100g/L, hematocrit (Hct) < 25% ? Prothrombin time (PT)=1.5 times the normal value ?In patients with severe dysfunction of liver and kidney, ALT/AST exceeds the normal high limit by more than 5 times ?Long-term use of chemotherapy drugs, long-term use of immunosuppressants ? Warfarin therapy ? Have other blood system diseases ? Compliance is not good, can not insist on completing the interview

Design outcomes

Primary

MeasureTime frame
thromboelastography;

Secondary

MeasureTime frame
previous history;four blood coagulation indexes;blood fat;Type of bypass vessel;blood routine examination;

Countries

China

Contacts

Public ContactDanna Wu

Hainan General Hospital

wudannachangchang@163.com+86 188 7616 0135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026